胆囊癌治疗的若干热点问题

doi:10.16139/j.1007-9610.2019.02.003

摘要/Abstract

中图分类号:

R735.8

程石, 赵修浩. 胆囊癌治疗的若干热点问题[J]. 外科理论与实践, 2019, 24(02): 100-104.

[1] Zaidi MY, Maithel SK.Updates on gallbladder cancer management[J]. Curr Oncol Rep,2018,20(2):21.
[2] Ethun CG, Postlewait LM, Le N, et al.Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. JAMA Surg,2017,152(2):143-149.
[3] Addeo P, Centonze L, Locicero A, et al.Incidental gallbladder carcinoma discovered after laparoscopic cholecystectomy: identifying patients who will benefit from reoperation[J]. J Gastrointest Surg,2018,22(4):606-614.
[4] Creasy JM, Goldman DA, Gonen M, et al.Predicting residual disease in incidental gallbladder cancer: risk stratification for modified treatment strategies[J]. J Gastrointest Surg,2017,21(8):1254-1261.
[5] 田远虎. 腹腔镜胆囊切除术术中或术后发现意外胆囊癌的外科治疗[J]. 中华外科杂志,2015,53(2):135-139.
[6] Duffy A, Capanu M, Abou-Alfa GK, et al.Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre(MSKCC)[J]. J Surg Oncol,2008, 98(7):485-489.
[7] Du J, Yang XW, Wen ZJ, et al.Relationship between prognosis and time interval from cholecystectomy to reo-peration in postoperative incidental gallbladder carcinoma[J]. Chin Med J (Engl),2018,131(20):2503-2505.
[8] Lee H, Kwon W, Han Y, et al.Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis[J]. J Hepatobiliary Pancreat Sci,2018,25(2):131-141.
[9] 段安琪, 邱应和, 易滨, 等. 意外胆囊癌在腹腔镜切除术中或术后的处理对策[J]. 临床和实验医学杂志,2016,15(1):62-64.
[10] Goetze TO, Paolucci V.The prognostic impact of positive lymph nodes in stages T1 to T3 incidental gallbladder carcinoma: results of the German Registry[J]. Surg Endosc,2012,26(5):1382-1389.
[11] Sternby Eilard M, Lundgren L, Cahlin C, et al.Surgical treatment for gallbladder cancer - a systematic literature review[J]. Scand J Gastroenterol,2017,52(5):505-514.
[12] 孙静锋, 赵何伟, 郑苏文, 等. 根治性切除及单纯胆囊切除对Ⅱ期胆囊癌疗效的Meta分析[J]. 中国肿瘤外科杂志,2013,5(1):33-36.
[13] Ito H, Ito K, D'Angelica M, et al. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment[J]. Ann Surg,2011,254(2):320-325.
[14] 程石. 重视意外胆囊癌再次手术的规范[J]. 临床外科杂志,2017,25(6):423-425.
[15] Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer an international multicenter study[J]. Ann Surg,2015,261(4):733-739.
[16] Vinuela E, Vega EA, Yamashita S, et al.Incidental gallbladder cancer: residual cancer discovered at oncologic extended resection determines outcome: a report from high- and low-incidence countries[J]. Ann Surg Oncol,2017,24(8):2334-2343.
[17] 中华医学会外科学分会胆道外科学组. 胆囊癌诊断和治疗指南(2015版)[J]. 中华消化外科杂志,2016,14(3):411-419.
[18] Piccolo G, Piozzi GN.Laparoscopic radical cholecystectomy for primary or incidental early gallbladder cancer: the new rules governing the treatment of gallbladder cancer[J]. Gastroenterol Res Pract,2017,2017:8570502.
[19] Berger-Richardson D, Chesney TR, Englesakis M, et al.Trends in port-site metastasis after laparoscopic resection of incidental gallbladder cancer: A systematic review[J]. Surgery,2017,161(3):618-627.
[20] Maker AV, Butte JM, Oxenberg J, et al.Is port site resection necessary in the surgical management of gallbladder cancer?[J]. Ann Surg Oncol,2012,19(2):409-417.
[21] Ethun CG, Postlewait LM, Le N, et al.Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium[J]. J Surg Oncol,2017,115(7):805-811.
[22] 汤朝晖, 田孝东, 魏妙艳, 等. 美国癌症联合委员会胆道恶性肿瘤分期系统(第8版)更新解读[J]. 中国实用外科杂志,2017,37(3):248-254.
[23] Lee W, Jeong CY, Jang JY, et al.Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study[J]. Surgery,2017,162(3):515-524.
[24] 汤朝晖, 刘颖斌, 全志伟. 肿瘤分期对胆囊癌术式选择及预后判断临床意义研究[J]. 中国实用外科杂志,2011,31(3):224-227.
[25] Smith-Cohn MA, Gill D, Voorhies BN, et al.Case report: pembrolizumab- induced type 1 diabetes in a patient with metastatic cholangiocarcinoma[J]. Immunotherapy,2017,9(10):797-804.
[26] Czink E, Kloor M, Goeppert B, et al.Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer[J]. Cold Spring Harb Mol Case Stud,2017,3(5):a001974.
[27] 陈亚进, 陈贤清. 程序性细胞死亡蛋白-1及其配体抑制剂在胆道肿瘤治疗中的现状与前景[J]. 中华消化外科杂志,2018(3):219-224.

胆囊癌治疗的若干热点问题

Several hot topics on treatment of gallbladder cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨盈赤, 庞凯, 张忠涛. 新辅助放疗联合免疫治疗对直肠癌微创术式应用的影响[J]. 外科理论与实践, 2023, 28(03): 186-189.
[2]	韩序, 王文权, 楼文晖, 刘亮. 免疫检查点抑制剂治疗胃肠胰神经内分泌肿瘤的进展[J]. 外科理论与实践, 2023, 28(03): 267-272.
[3]	邢颖, 程石. 胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114.
[4]	李建芳, 余俊贤, 严超, 朱正纲, 刘炳亚. 胃癌基础与转化研究的热点问题[J]. 外科理论与实践, 2023, 28(01): 7-16.
[5]	张天羽, 周东, 洪桢. 《儿童抗NMDAR脑炎治疗的国际共识推荐》解读[J]. 诊断学理论与实践, 2022, 21(06): 677-683.
[6]	任佳逸, 糜坚青. 新型抗体类药物在急性B淋巴细胞白血病中的治疗进展[J]. 内科理论与实践, 2022, 17(06): 463-467.
[7]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[8]	于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52.
[9]	王思颖，郑幸玲，覃文新. 癌症患者能否长期生存？[J]. 上海交通大学学报, 2021, 55(Sup.1): 49-50.
[10]	宗春燕，沈键锋. 免疫治疗能否治愈肿瘤？[J]. 上海交通大学学报, 2021, 55(Sup.1): 53-54.
[11]	罗雅方, 徐倩玥, 余红. 尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展[J]. 诊断学理论与实践, 2021, 20(06): 592-595.
[12]	杨哲宇, 陆骋豪(综述), 蔡伟(审校). 浆细胞样树突状细胞与肿瘤免疫研究的新进展[J]. 外科理论与实践, 2021, 26(06): 568-572.
[13]	苏长青. 从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.
[14]	周艺, 杨莉. 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[15]	司安锋, 雷正清, 杨平华, 江涛, 王轩, 程张军. 巨块型肝内胆管癌术后经肝动脉化疗栓塞的有效性[J]. 外科理论与实践, 2021, 26(02): 138-143.